

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
June 11, 2021**

**ORDER GRANTING CONFIDENTIAL TREATMENT  
UNDER THE SECURITIES ACT OF 1933**

**Unity Biotechnology, Inc.**

**File No. 333-224163 - CF#36154**

Unity Biotechnology, Inc. submitted an application under Rule 406 requesting an extension of a previous grant of confidential treatment for information it excluded from the Exhibits to a Form S-1 registration statement filed on April 5, 2018, as amended.

Based on representations by Unity Biotechnology, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.19(a)	through April 23, 2031
Exhibit 10.19(b)	through April 23, 2031
Exhibit 10.19(d)	through April 23, 2031
Exhibit 10.19(e)	through April 23, 2031
Exhibit 10.19(f)	through April 23, 2031
Exhibit 10.19(g)	through April 23, 2031
Exhibit 10.20	through April 23, 2031
Exhibit 10.21	through April 23, 2031

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Robert Errett  
Chief, Disclosure Management Office